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COMMENTARY
Clinical Data: Sources and Types, Regulatory Constraints, 
Applications
Stanley C. Ahalt1,†, Christopher G. Chute2, Karamarie Fecho1,*, Gustavo Glusman3, Jennifer Hadlock3, Casey Overby Taylor2, 
Emily R. Pfaff4, Peter N. Robinson5, Harold Solbrig2, Casey Ta6, Nicholas Tatonetti6 and Chunhua Weng6 The Biomedical Data 
Translator Consortium
Access to clinical data is critical for the advance-
ment of translational research. However, the nu-
merous regulations and policies that surround 
the use of clinical data, although critical to ensure 
patient privacy and protect against misuse, often 
present challenges to data access and sharing. In 
this article, we provide an overview of clinical 
data types and associated regulatory constraints 
and inferential limitations. We highlight several 
novel approaches that our team has developed 
for openly exposing clinical data.
BACKGROUND
Recognizing the need to respect and protect patient pri-
vacy, numerous regulations have been established to gov-
ern the use of clinical data by researchers, including the 
federal Health Insurance Portability and Accountability 
Act of 1996 (HIPAA) and the European Union General Data 
Protection Regulation. Institution- specific guidelines and 
governing bodies such as institutional review boards (IRBs) 
also address research involving patient data and other sen-
sitive data available in electronic medical records (e.g., ad-
ministrative data), in part as a result of concerns regarding 
the liability of healthcare providers and institutions.1,2
The Biomedical Data Translator (Translator) program, 
funded by the National Center for Advancing Translational 
Sciences, aims to facilitate the transformation of basic sci-
ence discoveries into clinically actionable knowledge and 
leverage clinical expertise to drive research innovations.3,4 
Access to clinical data is central to the vision of the program. 
Yet, the program’s dedication to open science adds com-
plexity to the regulatory, technical, and cultural challenges 
that already surround access to clinical data.
We review here the types of clinical data sets that can 
be derived from paper or electronic medical records, their 
applications and limitations, and their associated regulatory 
constraints, focusing primarily on compliance requirements 
mandated in the United States under HIPAA (Table 1). We 
briefly describe several clinical data types that are com-
monly employed in clinical and translational research, in-
cluding fully identified clinical data, HIPAA- limited clinical 
data, deidentified clinical data, and synthetic data. We high-
light several novel approaches for openly exposing clini-
cal data that we have developed as part of the Translator 
program, namely, HIPAA Safe Harbor Plus (HuSH+) clinical 
data, clinical profiles, Columbia Open Health Data (COHD), 
and the Integrated Clinical and Environmental Exposures 
Service (ICEES).
TYPES OF CLINICAL DATA SETS
Fully identified clinical data sets
Fully identified clinical data sets comprise observational 
patient data, including direct patient identifiers (i.e., pro-
tected health information (PHI)), as defined in the privacy 
rule issued under HIPAA. Access requires a specific re-
search hypothesis, study approval by an IRB, a full or partial 
waiver of HIPAA- informed consent, and typically a secure 
workspace. For investigators not affiliated with a specific 
institution, additional regulations and approvals may apply, 
including a data use agreement (DUA) with the provider in-
stitution. Fully identified clinical data sets may be used for 
clinical interpretation and scientific inference and discovery. 
However, as with all data sets but especially observational 
administrative data sets, issues of data quality and integrity 
must be taken into account when drawing conclusions.1
HIPAA- limited clinical data sets
HIPAA- limited clinical data sets comprise observational pa-
tient data with limited PHI: dates such as admission, dis-
charge, service, and dates of birth and death; city, state, and 
five digits or more zip codes; and ages in years, months, 
days, or hours. HIPAA- limited clinical data sets may be 
used or disclosed for purposes of research, public health, 
or healthcare operations without obtaining patient authori-
zation or a waiver of HIPAA- informed consent but with IRB 
approval and (in some cases) a fully executed DUA. HIPAA- 
limited clinical data sets may be used for clinical interpre-
tation and scientific inference and discovery but with the 
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understanding that certain data elements have been re-
moved from the data and/or transformed (e.g., age vs. birth 
date).
Deidentified clinical data sets
Deidentified clinical data sets comprise observational 
patient data from which all PHI elements have been re-
moved. Access to deidentified clinical data sets does 
not require IRB approval, although an IRB Request for 
Determination of Human Subjects Research is advised. 
In addition, a fully executed DUA is sometimes required. 
Deidentified clinical data sets may be used for clinical 
interpretation and scientific inference and discovery 
but to a lesser extent than HIPAA- limited clinical data 
sets because of the fact that key variables or covariates 
may have been removed from the data. For instance, 
dates are  required to make inferences regarding sea-
sonal patterns in clinical outcomes and correlations with 
Table 1 Clinical data types, regulatory access restrictions, and applications
Clinical data type Brief description Regulatory access restrictions Applications
Fully identified 
clinical data sets
Observational patient data derived from 
paper- based or electronic medical records
IRB approval is required; an executed 
data use agreement is possibly 
requireda
Clinical interpretation and 
scientific inference and 
discovery
HIPAA- limited 
clinical data sets
Observational patient data containing only a 
limited set of HIPAA- defined PHI
IRB approval is required; an executed 
data use agreement is possibly 
requireda
Clinical interpretation and 
scientific inference and 
discovery, but with the 
understanding that certain 
data elements have been 
removed from the data and/or 
transformed
Deidentified clinical 
data sets
Observational patient data, but with all HIPAA- 
defined PHI elements removed
IRB approval is not requiredb; IRB 
“Request for Determination of 
Human Subjects Research” is 
typically recommended; an executed 
data use agreement is possibly 
required
Clinical interpretation and 
scientific inference and 
discovery, but with the 
understanding that inferences 
regarding time and potentially 
other factors cannot be made
HuSH+ clinical data 
sets
Observational patient data, fully compliant with 
HIPAA Safe Harbor, but unlike deidentified 
clinical data sets, HuSH+ clinical data sets have 
been altered such that (i) real patient identifiers 
(including geocodes) have been replaced with 
random patient identifiers and (ii) dates 
(including birth dates) have been shifted by a 
random number of days (maximum of 
± 50 days), with all dates for a given patient 
shifted by the same number of days 
Data are derived from UNC Health Care System
An executed data use agreement is 
requiredc
Clinical interpretation and 
scientific inference and 
discovery, but with the 
understanding that any 
inferences based on date/
time and location (geocode) 
cannot be made with 
precision, and all other 
inferences must consider 
date/time and location as 
potentially hidden covariates
Clinical profiles Statistical profiles of disease and associated 
phenotypic presentation derived from 
observational patient data 
Data are derived from Johns Hopkins Medicine
IRB approval is required to generate 
clinical profiles; no other restrictions 
apply
Clinical interpretation and 
scientific inference, but with 
the understanding that the 
data represent statistical 
profiles
Synthetic clinical 
data sets
Realistic, but not real, observational patient data 
generated statistically using population 
distributions of observational patient data
None Feasibility assessments and 
algorithm validation; 
generation of clinical profiles
COHD Counts of observational clinical co- occurrences 
(e.g., co- occurrences of specific diagnoses and 
prescribed medications), as well as their 
relative frequency and observed–expected 
frequency ratio 
Data are derived from Columbia University 
Irving Medical Center
None Clinical interpretation and 
scientific inference, but with 
the understanding that the 
data are restricted to 
co- occurrences
ICEES Patient- level or visit- level counts of observational 
patient data integrated at the patient and visit 
level with a variety of environmental exposures 
derived from multiple public data sources 
Data are derived from UNC Health Care System 
and a variety of public data sources on 
environmental exposures
IRB approval is required to generate 
ICEES integrated feature tables; no 
other restrictions apply
Clinical interpretation and 
scientific inference, but with 
the understanding that the 
raw data have been 
transformed (e.g., binned or 
categorized)
COHD, Columbia Open Health Data; HIPAA, Health Insurance Portability and Accountability Act; HuSH+, HIPAA Safe Harbor Plus; ICEES, Integrated Clinical 
and Environmental Exposures Service; IRB, institutional review board; PHI, protected health information; UNC, University of North Carolina.
aIndividual institutions may require a secure workspace for data access and use. bWhile HIPAA and IRB regulations do not apply, institutional approvals may 
be required. cHuSH+ clinical data sets were conceptualized and created by UNC as part of the National Center for Advancing Translational Sciences–funded 
Biomedical Data Translator program. The institution requires a fully executed data use agreement for access to the data.
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natural disasters, system- related issues such as protocol 
changes, and regulatory issues such as new black- box 
warnings.
HuSH+ clinical data sets
HuSH+ clinical data sets were created by Translator team 
members as a hybrid deidentification approach that is com-
pletely compliant with HIPAA and provides restricted access 
to observational patient data from the UNC Health Care 
System. HuSH+ clinical data sets differ from deidentified clin-
ical data sets in that (i) real patient identifiers (including geo-
codes) have been replaced with random patient identifiers and 
(ii) dates (including birth dates) have been shifted by a random 
number of days (maximum of ± 50 days), with all dates for a 
given patient shifted by the same number of days. Access to 
HuSH+ clinical data does not require IRB approval but does 
require a fully executed DUA per institutional mandate. HuSH+ 
clinical data sets may be used in a limited fashion for clini-
cal interpretation and scientific inference and discovery. The 
main considerations are that any inferences based on date/
time and location (geocode) cannot be made with precise ac-
curacy or correlated with seasonal trends or specific events, 
and all other inferences must consider date/time and location 
as potentially hidden covariates. 
Clinical profiles
Clinical profiles have been developed as part of the Translator 
program and represent statistical profiles of disease and asso-
ciated phenotypic presentations derived from observational 
patient data from Johns Hopkins Medicine using the Health 
Level Seven International Fast Healthcare Interoperability 
Resources common data model.  At present, clinical profiles 
include data on demographics, diagnoses, disease comor-
bidities, symptoms, medications, procedures, and labora-
tory measures. IRB approval is required to generate clinical 
profiles but once generated, clinical profiles can be openly 
shared. Institutional restrictions may apply, however. Clinical 
profiles can be used for clinical interpretation and scientific 
inference and discovery but with the understanding that they 
represent statistical summaries of patient populations and 
only indirectly represent patient- level observations. Multiple 
computational tools and example output files are openly avail-
able for creating and using clinical profiles (see Supplemental 
Information on Clinical Profiles in Further Reading). 
Synthetic clinical data sets
Synthetic clinical data sets comprise realistic (but not real) 
data generated statistically by applying simulation techniques 
to population distributions of observational patient data. 
Synthetic clinical data sets can be openly shared. A publicly 
available example, the Synthetic Mass data set, was gener-
ated using the Synthea method5 to simulate patient- level and 
population- level data on patients who reside in the state of 
Massachusetts. A similar open effort is Simulacrum, which 
is based on observational patient data held by Public Health 
England’s National Cancer Registration and Analysis Service. 
The data include realistic patient histories with clinically rel-
evant patient encounters; as such, the data can be used for 
feasibility assessments and algorithm validation but not for 
clinical interpretation or scientific inference and discovery.
COHD
Translator team members have pioneered the use of clin-
ical co- occurrence tables as part of the COHD initiative.6 
COHD provides open access to observational patient data 
from Columbia University Irving Medical Center in the form 
of co- occurrence counts of pairs of concepts or clinical 
feature variables (e.g., medications and diagnoses), as well 
as their relative frequency and observed–expected fre-
quency ratio. The data are publicly accessible via an open 
web interface or Application Programming Interface.  Risks 
to patient privacy are mitigated by excluding rare features 
(counts ≤ 10) and perturbing the counts according to the 
Poisson distribution. The data can be used to derive in-
sights into questions of clinical relevance and importance 
for translational research. For instance, an individual user 
may wish to know the frequency of asthma among African 
American patients (Figure 1a). A search of the COHD ser-
vice reveals that there are 11,716 African American pa-
tients with a diagnosis of asthma among 208,438 African 
American patients (5.62%). For comparison, a second 
search reveals that there are 29,913 white patients with a 
diagnosis of asthma among 601,167 white patients (4.98%).
ICEES
ICEES was designed by Translator team members as a 
novel extension of COHD.7 Specifically, ICEES permits 
open access to observational patient data from the UNC 
Health Care System that have been integrated at the pa-
tient and visit level with environmental exposures data (e.g., 
airborne and roadway pollutants, socioeconomic factors) 
derived from multiple public sources. A complex data ex-
traction and integration software pipeline has been devel-
oped to create ICEES integrated feature tables.8 The tables 
are generated using PHI (geocodes and dates), but the data 
are then binned or recoded and stripped of PHI. Thus, the 
ICEES pipeline must be executed under an approved IRB 
protocol, but subsequent steps are not subject to IRB reg-
ulation, and ICEES is publicly accessible via an Application 
Programming Interface. ICEES provides a number of func-
tionalities for clinical interpretation and scientific inference 
and discovery. For example, Figure 1b demonstrates that 
for COHORT:60 (African Americans with asthma- like condi-
tions in calendar year 2010), the percentage of patients with 
two or more annual emergency department or inpatient vis-
its for respiratory issues is higher among patients with high 
average daily exposure to particulate matter ≤ 2.5 μm in 
diameter than among patients with low average daily expo-
sure to particulate matter ≤ 2.5 μm in diameter (21.10% vs. 
8.90%, P < 0.0001, N = 6,379), thus replicating published 
literature on the association between airborne pollutant ex-
posures and asthma exacerbations.9 The data additionally 
suggest that African Americans with asthma- like conditions 
have relatively high exposure to particulate matter, with 
~ 95% of the cohort exposed to ≥ 9.63 μg/m3 average daily 
particulate matter ≤ 2.5 μm in diameter.
Clinical fingerprints
Although not a new clinical data type per se, Translator 
teams have been working to develop privacy- preserving 
analytic approaches to visualize and compare patient data, 
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Figure 1 Example queries, including input parameters and output, for Columbia Open Health Data (COHD) (a) and the Integrated 
Clinical and Environmental Exposures Service (ICEES) (b). AvgDailyPM2.5Exposure = average daily patient exposure to PM2.5 (μg/m
3) 
over a 1- year study period; TotalEDInpatient Vists = total number of emergency department or inpatient visits for respiratory issues 
during a 1- year study period. The study period shown here is for calendar year 2010. AvgDailyPM2.5Exposure <3 range: 1.58, 9.63 μg/
m3; AvgDailyPM2.5Exposure ≥3 range: 9.63, 17.33 μg/m3. ID, identifier; PM2.5, airborne particulate matter ≤2.5 μm in diameter. 
(a)
(b)
 COHD example queries 
Input: Asthma (ID #317009) and Black or African American (ID #8516)
Output:  
Input: Asthma (ID #317009) and White (ID #8527)
Output: 
 ICEES example query 
Input: 
Feature variables: AvgDailyPM2.5Exposures < 3, TotalEDInpatientVisits < 2 
Version of data: 1.0.0 
Table: patient 
Year: 2010 
Cohort ID: COHORT:60 
Output:* 
+----------------------------+------------------------------+-------------------------------+---------+
| feature                    | TotalEDInpatientVisits < 2   | TotalEDInpatientVisits >= 2   | | 
+============================+==============================+===============================+=========+ 
| AvgDailyPM2.5Exposure < 3  | 297    91.10% | 29 8.90% | 326 | 
| | 5.85%  4.66% | 2.22%  0.45% | 5.11%   | 
+----------------------------+------------------------------+-------------------------------+---------+
| AvgDailyPM2.5Exposure >= 3 | 4776    78.90% | 1277    21.10% | 6053    | 
| | 94.15%  74.87% | 97.78%  20.02% | 94.89%  | 
+----------------------------+------------------------------+-------------------------------+---------+
|                            | 5073                         | 1306                          | 6379    | 
| | 79.53% | 20.47% | 100.00% | 
+----------------------------+------------------------------+-------------------------------+---------+
+-------------+---------------+
|     p_value |   chi_squared | 
+=============+===============+ 
| 3.16593e-06 | 28.2841 | 
+-------------+---------------+
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including genomic data and clinical records in semistruc-
tured JavaScript Object Notation or eXtensible Markup 
Language formats.  Genomic data typically consist of lists 
of variants relative to a reference allele sorted by position. 
Genome fingerprints capture the unique patterns gener-
ated by pairs of consecutive single- nucleotide variants 
as patient- level matrices or fingerprints.10 The correlation 
between two fingerprints reflects the degree of related-
ness between two genomes. Clinical fingerprints simi-
larly transform clinical records from the Fast Healthcare 
Interoperability Resources format into numerical vectors 
that greatly simplify their comparison. Translator team 
members are working to adapt this methodology for ap-
plication to the ICEES integration pipeline and incorpora-
tion into the ICEES integrated feature tables.
CONCLUSION
In this article, we described various types of clinical data 
sets and associated inferential limitations and regulatory 
constraints, focusing primarily on compliance requirements 
mandated in the United States under HIPAA. We highlighted 
several novel approaches that we have developed as part 
of the Translator program to openly expose observational 
patient data, while respecting and protecting patient pri-
vacy. We recognize that each of these approaches retains 
a residual risk of patient reidentification; thus, we continue 
to work with experts in regulatory protections and com-
puter security to ensure that those risks remain minimal. 
Although the Translator approaches are designed to be 
disease- agnostic and generalizable, they were developed 
to comply with HIPAA and institutional guidelines; as such, 
our approaches may need to be modified prior to adoption 
elsewhere. Nonetheless, through these open services, we 
hope to accelerate clinical and translational science and 
foster biomedical discovery.
Supporting Information. Supplementary information accompa-
nies this paper on the Clinical and Translational Science website (www.
cts-journal.com). The Further Reading includes supplementary in-
formation on Clinical Profiles, Synthetic Clinical Datasets, COHD, and 
ICEES, as well as relevant regulatory information and information on 
related large-scale patient de-identification and data-sharing efforts.
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